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Abstract. Results obtained by competitive protein binding assay (PBA) and a 
solid-phase radioimmunoassay (RIA) for cortisol were compared in 157 samples 
from 100 psychiatric patients given a dexamethasone suppression test (DST). 
Cortisol levels in plasma samples obtained at 8:00 a.m. or 4:00 p.m. the day 
following 1 .O mg dexamethasone orally at bedtime ranged from 0 to 30 pg/ dl and 
correlated closely (r q 0.96). However, RIA gave values that were consistently and 
significantly lower (average = 8.9%) than those obtained by PBA. When samples 
were further assayed by a specific RIA for corticosterone, there was a strong 
correlation between cortisol and corticosterone RIA values (r = 0.79), and corticos- 
terone (7.8% of cortisol levels) accounted for most of the difference between PBA 
and RIA for cortisol. The relationship between results of the two cortisol assay 
methods can be expressed (in pg/dl) by the equation: RIA = 0.92(PBA) - 0.10. 
based on findings obtained in a separate analysis of 127 samples with cortisol 
values in the O-10 pg/dl range, critical to the valid interpretation of the DST in 
melancholia. A reported criterion of a “positive” DST in psychiatry, of plasma 
cortisol of > 5.0 pg/dl has been suggested by use of a PBA. Use of the present RIA 
required that this value be adjusted downward, at least to 4.5 pg/ dl; application of 
this criterion increased the clinical sensitivity of the DST by 10%. We urge local, 
independent verification of criteria to define the DST as “positive” in each labora- 
tory and with each method of .assay. 
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To date, plasma cortisol (hydrocortisone, 17-hydroxycorticosterone, or compound F) 
has been measured by the following methods: fluorometric, double-isotope derivative, 
competitive protein binding assay (PBA), and radioimmunoassay (RIA). The compet- 
itive protein binding method (Murphy, 1967) requires only small blood samples, is 
sensitive, inexpensive, and simple. Human cortisol binding globulin (transcortin), the 
selective binding protein used by this method, is not specific for cortisol, as it also 
Timothy E. Wilens was a predoctoral research assistant at Harvard Medical School from the University of 
Michigan School of Medicine. George W. Arana, M.D., is Assistant Professor and Ross J. Baldessarini. 
M.D.,-is Professor of Psychiatry, Department of Psychiatry, Harvard Medical School. Cornelia Cremens. 
M.T., is Coordinator of Clinical Laboratory Services, McLean Hospital. (Reprint requests to Dr. G.W. 
Arana, Mailman Research Center, McLean Hospital, I I5 Mill St., Belmont, MA 02178, USA.) 
0165- 178 I / 83/0000-OOOO/ $3.00 @ Elsevier Science Publishers 
200 
binds corticosterone, 1 I-deoxycortisol, cortisone, and other steroids; accordingly, this 
technique often yields somewhat higher values for cortisol than do other more 
selective methods (Farmer and Pierce, 1974; Jiang et al., 1975; Thijssen et al., 1980; 
Ritchie and Carroll, 198 1). Because of the generally greater specificity and excellent 
sensitivity of many RIA techniques, they have become an increasingly accepted 
method for measurement of cortisol for clinical purposes (Kumar et al., 1976; Brock et 
al., 1978; Thijssen et al., 1980). One system of RIA, a solid-phase technique which uses 
‘251-labeled cortisol and is marketed by Scientific Products, is used to measure cortisol 
levels here and in many other hospital laboratories. 
Numerous efforts have been made to apply endocrinological methods to aid in the 
diagnosis of major endogenomorphic depression (melancholia) (Baldessarini, 1983). 
These include assays of cortisol, notably in the dexamethasone suppression test (DST) 
(Carroll et al., 1981; Carroll, 19820, 1982b). Dexamethasone, a synthetic glucocorti- 
coid, suppresses limbic-hypothalamic-pituitary-adrenocortical activity, presumably 
by mimicking physiologic feedback inhibition of the release of pituitary adrenocorti- 
cotropic hormone (ACTH) through the central nervous system (CNS). When oral 
dexamethasone (1 .O mg) is given at II:00 or II:30 p.m., normal subjects and psychiat- 
ric controls maintain plasma cortisol suppression below 5.0 pg/dl for 24 hours or 
longer, as assessed by a PBA method (Carroll et al., 1981). Those psychiatric patients 
who have higher plasma cortisol levels or “escape” dexamethasone suppression within 
24 hours are considered to have an abnormality of CNS-pituitary mechanisms that 
regulate ACTH. and thus adrenal glucocorticoid secretion. It has been proposed that 
such dysregulation of cortisol secretion may be selective for melancholia (Carroll et 
al., 198 1), although the test is being found to be “positive” in an increasing range of 
conditions (Arana et al., 1982; Finklestein et al., 1982). 
Recently reported criterion values that define a “positive” DST by plasma or serum 
cortisol levels 3 5 pg/dl have been proposed, based on use of a competitive protein 
binding assay (Carroll et al., 198 1). Few reports have directly compared the PBA and 
increasingly common RIA methods in the range reported to be critical in differentiat- 
ing melancholia from other psychiatric illesses (Kumar et al.. 1976; Brock et al., 1978) 
and none has involved a psychiatric population. Since several previous studies already 
cited suggest that cortisol values obtained by PBA may be somewhat higher than those 
obtained using RIA, there is a potential for a “false negative” interpretation of the 
DST with a more specific RIA. Thus, it is of interest to compare the two commonly 
used assay methods directly in a psychiatric population. Of particular clinical interest 
is the range believed to be critical for the DST in depression (l-10 pg/dl), as well as 
higher levels as may be encountered with the DST in endocrinological disorders such 
as Cushing’s syndrome and in some cases of depression (Liddle, 1960). 
Methods 
Competitive Protein Binding (PBA) Assay. Cortisol in human plasma was assayed using 
modifications of the PBA assay of Murphy (1967). [I ,2-‘H] Corticosterone (40 Cij mmole) was 
obtained from New England Nuclear (Boston, MA). Without further purification. a 250 PCi 
vial of this labeled steroid was diluted to 25.0 ml with absolute ethanol (redistilled. IMC 
Chemical, Terre Haute. IN) and stored at -20°C. A stock solution of human cortisol-binding 
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globulin (transcortin) was prepared by adding 1 .O ml of the diluted 3H-corticosterone to I .5 ml 
ethanol, 200 ml distilled water, and 5.0 ml of pooled normal human plasma~all adjusted to 250 
ml with distilled water (final transcortin solution q 270, w/v). Just before use, an amount 
sufficient for an assay was allowed to warm to room temperature. Standard solutions of 
authentic unlabeled cortisol (Sigma Chemical, St. Louis, MO) in absolute ethanol were pre- 
pared by serial dilutions to provide final concentrations of 0.0.5, 1.2.5, IO and 20 ng/0.2 ml. all 
stored at -20°C. Standard plots were routinely prepared for each assay using triplicate samples 
of the authentic cortisol solutions. To I5 x 85 mm disposable borosilicate glass tubes (Scientific 
Products, McGaw Park, IL), 0.5 ml samples of human plasma were extracted into 1.0 ml 
ethanol, vortexed. and centrifuged at 2,000g for 12 minutes; 0.2 ml portions of the ethanol- 
cortisol phase were aliquoted in duplicate. Control samples were routinely included which 
assayed pooled normal human plasma (Blood Bank, Massachusetts General Hospital), treated 
as above except that 0. I, 0.2, or 0.3 ml of the extract of control plasma was added to duplicate 
tubes. All tubes containing authentic cortisol samples or control plasma specimens were then 
dried under a stream of air in a 45’C water bath. 
The PBA assay was performed as described by Murphy (1967) with Florisil (Fischer Scien- 
tific, Fair Lawn, NJ) as the adsorbant to remove unbound 3H-steroid molecules. Briefly, I .O ml 
of the diluted 3H-corticosterone solution already described was added to each assay tube, which 
was immediately vortexed and incubated at 45°C for IO minutes. Samples were removed to an 
ice bath for 20 minutes. Preweighed Florisil(40 mg) was added to each tube: tubes were shaken 
at room temperature for 2 minutes, returned to the ice bath for IO minutes and centrifuged at 
2,000 g for 6 minutes. A 0.5 ml aliquot of the upper phase (containing ‘H-corticosterone bound 
to transcortin) was removed to polypropylene scintillation counting vials (Research Products 
International. Mt. Prospect, IL) containing 5.0 ml of Liquiscint fluid (National Diagnostics, 
Somerville. NJ), and counted in a Packard 3320 scintillation spectrometer (Packard Instru- 
ments, Bedford. MA). Radioactivity counts were then accumulated and a standard plot was 
constructed as cortisol concentration per tube vs. the corresponding time necessary to attain 
20.000 counts per minute (CPM), sufficient to produce a counting error of < f I %. 
Solid-Phase Radioimmunoassay (RIA). Plasma cortisol also was determined by a solid- 
phase radioimmunoassay kit (Immu-Trace Cortisol R.I.A.) marketed by Scientific Products 
(McGaw Park, IL) and produced by Ventrex Laboratories (Portland. ME). Included in the kit 
are inert “sticks” impregnated with an antibody to cortisol, assay tubes, diluting buffer, wash 
solution (2 mM phosphate buffer,eH 7.4, cortisol standards and radioactive tracer reagent (in 
phosphate buffered isotonic saline, pH 5.8, containing dye, and 15 mM sodium hydroxide). 
Tubes were prepared in duplicate with 0.01 ml of either standard solutions of authentic cortisol, 
control pooled normal human plasma, or patient plasma samples. Then, I .O ml of the buffered 
tracer reagent was added to each tube, vortexed briefly, and an antibody “stick” was inserted. 
The tubes were incubated at room temperature for 30 minutes; the reaction was stopped by 
inverting all tubes and washing with 2.5 ml of wash solution. The tubes were reinverted; their 
edges were blotted, and they were placed (including antibody sticks) in a gamma scintillation 
spectrometer (Packard Instruments, Bedford, MA) to count the bound t2?-cortisol for I 
minute. The standard curve obtained in each assay was linearized by plotting (as a percentage) 
the ratio of CPM bound with standard:CPM bound with blank, vs. the log of the concentration 
of authentic cortisol standards. 
A similar, specific RIA was used to assay corticosterone in the same serum samples. This 
assay was based on materials obtained from Endocrine Sciences Labs. (Tarzana, CA), and 
extraction of samples with hexane and benzene to remove potentially interfering steroids (such 
as cortisol and progesterone), as described in detail elsewhere (Wilens et al., in press). 
Patient Samples. We studied 157 plasma samples from I32 tests performed between October 
1981 and July 1982 in 100 patients of the McLean Hospital. Records of all cases were reviewed 
to eliminate any patients being treated with medications (i.e., steroids) known to interfere with 
cortisol determinations. DSM-III (American Psychiatric Association, 1980) diagnoses of this 
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patient population included bipolar illness, melancholia, schizophrenia, and atypical psychosis. 
All 100 patients had dexamethasone suppression tests (DSTs) administered by giving 1 .O mg of 
dexamethasone orally at 11:30 p.m.; blood samples were obtained the next day in heparinized 
glass tubes, either at both 8:00 a.m. and 4:00 p.m. (50 samples) or only at 4:00 p.m. (107 
samples), according to Carroll et al. (1981; Carroll. 19826). 
Results 
Comparison of Cross-Reactions of Assays With Steroids (Table 1). The PBA 
method, using 3H-corticosterone as the index ligand and a cortisol binding globulin, 
tanscortin, as the selective binding agent, shows significant cross-reactions with 
I I-deoxycortisol, corticosterone, and cortisone (loo%), and weaker reactions with 
prednisone and prednisolone (2OYo and 1570, respectively). The RIA, using a specific 
antibody to cortisol and ‘251-cortisol as ligand, shows greater specificity, with appreci- 
able cross-reactions noted only with prednisolone, 11 -deoxycortisol, and prednisone 
(44.9%, 15.5%, and 4. I%, respectively), all of which are uncommon in normal human 
blood. 
Table 1. Cross-reactivity of steroids in the competitive 
protein binding method and solid phase radio- 
immunoassay for cortisol levels 
Percent cross-reaction 2 
Compound1 PBA3 RIA” 
Cortisol 100.0 100.0 
Corticosterone 100.0 1.5 
11-Deoxycortisol 100.0 15.5 
Cortisone 100.0 1.7 
Prednisone 20.0 4.1 
Prednisolone 15.0 44.9 
Dexamethasone 0.0 0.9 
1. Note that of these steroids, except for cortisol. only corticosterone is likely 
to be encountered in normal human plasma in appreciable levels f Krieger, 
19791. 
2. Effect relative to an equal weight of cortisol in percent. 
3. Murphy 119671 
4. Scientific Products Technical Report 11981 1. 
Comparison of Results With PBA and RIA for Cortisol. Cortisol concentrations 
of three different dilutions of pooled normal human plasma were determined in 10 
assays by both methods. Values of inter- and intra-assay coefficients of variation were 
calculated (Rodbard, 1974). An intra-assay coefficient of variation was calculated at 
the mean ratio of SD to the mean of six replicate determinations carried out in each of 
10 independent assays of pooled human serum, An interassay coefficient was similarly 
derived for the IO independent assays performed on different days. The PBA yielded 
less interassay variability than the RIA (7.1% vs. 11.3%, respectively). The PBA and 
RIA were similar. however, with respect to intra-assay coefficients of variation (6.27~ 
and 5.8%. respectively). 
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In Fig. 1 A, results for 157 individual specimens (from 100 patients) assayed by both 
PBA and RIA are compared. The mean (f SD) for these samples by PBA was 5.02 k 
5.5 1, and by RIA was 4.6 1 f 5.5 1 pg/ dl (difference q 8.9% which is significant by t test 
of related means,p < 0.005). A close correlation was found between the results of the 
twoassay methods(r=0.955,p<0.001; slope was0.95l;y-intercept= -0.166; Fig. 1A). 
While the difference in results between the two methods was not large, it appeared to 
be consistent and significant: the level by PBA was higher in 104 of 156 assays in which 
a difference occurred (66.7% of cases,p < 0.00 1 by sign test). The difference in slope of 
the observed Pearson product moment regression line from a theoretical, ideal slope 
of 1.0 was also statistically significant (by t test for slopes of lines, according to 
Kreyszig, 1970, and Zar, 1974,~ < 0.05). An expanded view is provided in Fig. 1 B for 
results of PBA vs. RIA between 0 and 10 pg/dl (n = 127)-a crucial range for 
interpretation of the DST for melancholia for which a criterion level of 3 5.0 pg/ dl has 
been suggested, based on a PBA (Carroll et al., 198 1). These results again indicate a 
close correlation (rz0.926) but somewhat greater deviation toward the PBA (slope q 
0.922, y-intercept = -0.098), and suggest that the criterion for a “positive” or abnormal 
DST most comparable to a value of 5.0 pg/dl by PBA should be adjusted downward 
to 4.5 pg/dl when the present RIA method for plasma cortisol is employed (Fig. 1). 
Fig. 1. Comparison of postdexamethasone plasma cortisol determinations 
(in pg/dl) by solid-phase radioimmunoassay (WA = y) vs. competitive pro- 




PROTEIN BINDING ASSAY 
A Computed linear regression analysis ylelded: r q 0.955, slope = 0.951, and y-intercept = -0.166 jn = 157 
samples!. 
8. Detailed comparison of results when both assay methods yield cortisol levels of 0 to 10.0 pg/dl in = 127 
samples, r = 0.926, slope = 0.922, and y-intercept = -0.096). Note the critical value of 5.0 pg/dl defined by the 
PBA method is apparently equivalent to 4.5 Mg/dl by RIA. 
204 
The assay of corticosterone by RIA revealed a mean value (* SD) of 2.72 + 3.07 
pg/dl (n = 136 samples). These values were correlated closely with RIA levels of 
cortisol in 136 of the same blood specimens (r = 0.794, n q 136,~ < 0.00 1). The mean ( + 
SD) ratio of corticosterone to cortisol by RIAs was 7.78 f 6.00% (n = 136). 
Discussion 
The PBA method detects not only cortisol ( 17-hydroxycorticosterone), the predomi- 
nant circulating adrenal glucocorticosteroid in man (Murphy, 1967) but also cross- 
reacts with less prevalent steroids such as 1 I -deoxycortisol, cortisone, corticosterone, 
and, to a lesser extent, prednisone and prednisolone (Table I). Of the less prevalent 
steroids, only corticosterone is believed to be present in human plasma in appreciable 
concentrations (reportedly ca. 4Yc those of cortisol) (Krieger, 1979) so that the nearly 
9% discrepancy between results of a PBA and a more specific RIA used here (Fig. I) 
evidently is at least partly accounted for by cross-reaction of corticosterone in the 
bindingassay(Table 1). Moreover, when a direct estimate of the possible contribution 
of corticosterone was made by RIA analysis for corticosterone in many of the present 
samples, the results indicated that corticosterone values were closely correlated with 
those of cortisol (Y = 0.79) and averaged 7.8 YG of the values for cortisol obtained by 
PBA. The present findings of a somewhat higher value for plasma cortisol by a PBA 
method than an RIA method are consistent with previous comparisons of similar PBA 
and RIA assays (Farmer and Pierce, 1974; Jiang et al., 1975; Brock et al., 1978; 
Thijssen et al., 1980; Ritchie and Carroll, 1981). However, in these previous studies, 
most of the plasma cortisol values being compared ranged from 10 to 30 pgjdl and 
involved fewer than 40 samples from medical patients. 
In the present study we analyzed 157 plasma specimens obtained at 8:00 a.m. and 
4:00 p.m., or only at 4:00 p.m., on the day following 1 mg of dexamethasone at bedtime 
in 100 psychiatric patients by both PBA and RIA methods; of these, 127 samples 
yielded apparent cortisol levels below 10 pgl’dl, as determined by both methods. The 
equation we calculated by computed linear analysis for these 127 most pertinent 
samples was: RIA = 0.92(PBA) - 0.10 (Fig. 1 B). Comparable equations reported by 
others and based largely on levels above IO pg/ dl were: RIA = 0.72(PBA) - 0.06 pg/ dl 
(Farmerand Pierce, 1974) and RIA=0.92(PBA)+0.05 pg/dl(Brocketal., 1978). The 
sensitivity of solid-phase RIA used in the study of Brock et al. (0.5 pg/dl) is only 
slightly lower than that of the PBA (0.2 pgidl) (Murphy, 1967). 
Because of the importance of the criterion value recommended for the interpreta- 
tion of the DST, the use of the value of 5.0 pg/ dl proposed from data obtained by PBA 
(Carroll et al.. 198 I) should evidently be adjusted to an RIA value of4.5 pg/dl with the 
RIA which we employed. “Questionable” or “borderline” values of cortisol of 3.5 to 
5.0 by PBA should, likewise, evidently be revised to about 3.0 to 4.5 pg/dl for our RIA 
results. The downward adjustment of the DST criterion level to 3 4.5 pug/d1 for the 
present RIA method, albeit slight, in this study led to the reconsideration of five 
previously defined “negative” DSTs as “borderline”abnorma1 and, more importantly, 
two previously questionable DSTs to be reinterpreted as positive or abnormal tests. 
Both of the latter cases were found (independent of the assessment of the RIA 
criterion) to meet DSM-III criteria for major depression (one was melancholic; the 
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other was in a mixed manic depressive state and yielded a strongly positive DST on 
repeat testing). This change in criterion for the results with our RIA thus led to an 
increase in sensitivity of the DST in this population of 10%. It is of interest that Rush et 
al. (1982) independently came to a similar conclusion based on an empirical decision 
to maximize the sensitivity of a DST procedure that used an RIA for cortisol. and 
recommended 4.0 pgj dl as an appropriate cut-off value, as Carroll (I 982~) has also 
suggested for RIA-based DST. Other investigators have also noted not only a ten- 
dency for some RIA assays of cortisol to yield lower values than PBA assays, but for 
others to yield equal or even higher values; that is, there is considerable variation 
between laboratories and specific antibody preparations (Dr. H.Y. Meltzer, personal 
communication, December, 1982). Accordingly, we conclude from the present results 
that the criterion for a “positive” DST may need to be revised downward when a more 
specific assay of cortisol than used previously is employed. More generally, we suggest 
that standards for interpretation of the DST require critical evaluation with each 
method or laboratory employed in the assay of cortisol. 
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